WuXi AppTec Co

WuXi AppTec Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of WuXi AppTec Co (603259.SS) as of Nov 8, 2026 is 60.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 88.92 % — a change of -31.50% (lower).

FCF Conversion

60.91 %

YoY

-31.50%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of WuXi AppTec Co is 2025 60.91 % . FCF Conversion Rate (FCF/EBITDA) of WuXi AppTec Co was 2024 88.92 % . It decreases by -31.50% lower compared to the previous year.

The WuXi AppTec Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-26.92 CNY
Jan 1, 2019
20.72 CNY
Jan 1, 2020
31.85 CNY
Jan 1, 2021
-46.04 CNY
Jan 1, 2022
7.38 CNY
Jan 1, 2023
95.73 CNY
Jan 1, 2024
88.92 CNY
Jan 1, 2025
60.91 CNY
The WuXi AppTec Co FCF Conversion history
YEARFCF ConversionYoY
60.91 %-31.50%
88.92 %-7.11%
95.73 %+1,197.34%
7.38 %-116.03%
-46.04 %-244.58%
31.85 %+53.70%
20.72 %-176.97%
-26.92 %-176.75%
35.07 %-57.21%
81.96 %-250.35%
-54.51 %-490.70%
13.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WuXi AppTec Co Stock analysis

What does WuXi AppTec Co do? WuXi AppTec Co Ltd is a Chinese company that was founded in 2000 and specializes in the development of customer-oriented services in the pharmaceutical research and in vitro diagnostics sectors. The company operates multiple facilities in China, the USA, Europe, and Singapore. The business model of WuXi AppTec is based on the development and provision of services to meet the needs of customers worldwide. This includes activities such as bioanalysis, chemical development, drug manufacturing, and regulatory compliance and quality assurance services. In terms of various industries, the company is divided into three main divisions. The Chemical Division specializes in chemical development and drug manufacturing. The team has expertise in synthesizing complex molecules, scaling up for clinical trials, manufacturing bulk products for commercial use, and supplying APIs for formulation. The company has state-of-the-art facilities and technologies to ensure high product quality and fast production time. The Medical Device Division provides in vitro diagnostics for the global market to enable rapid and reliable medical diagnosis. The focus is on developing innovative technologies and applications in the fields of oncology, infectious diseases, and neurology. The company has many partnerships with leading in vitro diagnostics companies to enhance the quality and reach of products and services. The Biological Division specializes in the development of biopharmaceutical products and services. This includes the development of monoclonal antibodies to the production of recombinant proteins. The services include process development, manufacturing, characterization, and analysis of biological products. WuXi AppTec is at the forefront of technology and provides its customers with state-of-the-art facilities and technologies. In addition to the aforementioned services, WuXi AppTec also offers solutions in the field of bioanalytics, supporting the development of analytical methods and drug validation. The company has also recently expanded into other areas, including the acquisition of NextCODE Health, a firm specializing in genetic diagnostics and analysis tools. The company operates internationally and collaborates with a wide range of customers in the pharmaceutical and biotech sectors. It is also part of a global network of companies focusing on therapeutic technologies, clinical trials, drug marketing, and other aspects of the pharmaceutical industry. WuXi AppTec aims to provide its customers with high-quality products and services that are scientifically sound and effective. The company invests in research and development to provide its customers with the latest technologies and discoveries. WuXi AppTec Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WuXi AppTec Co stock

FCF Conversion Rate (FCF/EBITDA) of WuXi AppTec Co is 60.91 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of WuXi AppTec Co changed from 88.92 % to 60.91 %, representing a -31.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) WuXi AppTec Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s WuXi AppTec Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — WuXi AppTec Co

All Key Metrics — WuXi AppTec Co